相关实验视频
Updated: May 16, 2025

13:32
High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
17.4K
神经退行性疾病中的天然产品:最近的进展和未来的前景
L Nahar1, R Charoensup2, Kulyash Kalieva3
1Laboratory of Growth Regulators, Palacký University and Institute of Experimental Botany, The Czech Academy of Sciences, Olomouc, Czechia.
Frontiers in pharmacology
|April 3, 2025
概括
天然产品在保护神经元免受阿尔茨海默氏症和帕金森症等神经退行性疾病的影响方面表现有前途. 需要进一步的研究,以克服有效临床使用的生物可用性和剂量方面的挑战.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 神经退行性疾病 (阿尔茨海默病,帕金森病,亨廷顿病) 由于有效治疗方法有限,因此存在重大治疗挑战.
- 在传统医学中历来使用的天然产品越来越多地因其在药物发现方面的潜力而得到认可.
- 这些化合物为神经保护和调节疾病途径提供了独特的特性.
研究的目的:
- 批判性地审查天然产品对神经退行症的神经保护作用.
- 阐明自然产品保护神经元的机制.
- 评估天然产品作为神经退行性疾病的补充疗法的潜力.
主要方法:
- 系统的文献搜索,以确保严格的研究选择,并尽量减少偏见.
- 从动物模型和细胞培养物中分析临床前数据.
- 评估现有的临床试验数据,并讨论挑战.
主要成果:
- 自然产品,包括多,类和类,通过减少神经元损伤,显示出显著的神经保护作用.
- 作用机制包括抗氧化,抗炎,细胞信号调节和线粒体支持.
- 临床前和一些临床研究显示出有希望的疗效,但生物可用性和标准化仍然是关键问题.
结论:
- 天然产品是新型神经保护剂和神经退行性疾病补充治疗的有希望的来源.
- 解决生物可用性,标准化和剂量等挑战对于临床翻译至关重要.
- 未来的研究应该专注于改进这些化合物,以提高疗效和安全性,以改善患者的治疗结果.
相关概念视频
Alzheimer's Disease: Overview
350
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
350
Parkinson's Disease: Overview
353
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
353
Alzheimer's Disease: Treatment
133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
86
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
86
Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
Neuroplasticity
252
Neuroplasticity reflects the brain's remarkable capacity to adapt and evolve, responding dynamically to learning, experiences, or injury by reorganizing its neural circuitry. This reorganization involves creating new neural connections and refining old ones through a series of biological processes that contribute to the brain's lifelong development and adaptability.
252

